Questions you may have.

Pre-Exposure Prophylaxis (PrEP) is a daily pill (Truvada®) that protects HIV-negative people from HIV infection. Several large clinical trials with HIV negative men and women have shown daily use of PrEP can prevent new HIV infections. In 2012, the U.S. Food and Drug Administration approved daily Truvada® as PrEP for HIV prevention.

Truvada® has been used in HIV treatment for more than 10 years, usually in combination with at least one other drug. Truvada®, as an HIV prevention medication, has been shown to be safe in clinical research studies. About 1 in 10 people reported some mild and short-lived side effects including gas, nausea, and headache.

A small number of people have experienced a decrease in kidney function that returned to normal when stopping PrEP. Your kidney function will be monitored while taking PrEP. Small losses of bone density have also been seen in people taking Truvada®; however, these changes have not been associated with bone fractures.

PrEP is not an HIV vaccine — you have to keep taking it to stay protected.

PrEP is also not a cure or treatment for HIV. HIV positive people need to be treated with combinations of at least 3 anti-HIV medications (PrEP only contains 2). Like with PrEP, people living with HIV/AIDS have to keep taking these drugs daily.

PrEP does not protect against other sexually transmitted infections (STDs), like gonorrhea, chlamydia, and syphilis, which can increase your risk of getting HIV.

PrEP is not intended to replace condoms. Condoms protect against other STDs, like gonorrhea and syphilis, which have been on the rise in the Bay Area.

There are no known drug interactions between Truvada (PrEP medication) and contraceptive hormones, and interactions between PrEP and hormone therapy for trans people are unlikely. Research studies suggest that PrEP is effective for trans people when taken as prescribed. The Stay Study will monitor hormone levels to confirm there are no interactions between PrEP and hormones.

PrEP (pre-exposure prophylaxis) and PEP (post-exposure prophylaxis) are two ways to prevent getting HIV. PEP is started within 72 hours AFTER a potential HIV exposure and then taken daily for 28 days. PrEP is started BEFORE potential HIV exposure, then taken daily during periods of risk. PrEP can be stopped if your risk changes, but you should talk with your health care provider first.

Yes. You will be given $50 in cash for each study visit you participate in. This is for your time and transportation costs. In addition, you are eligible to receive a monthly supply of Truvada® at no cost to you while you are in the study, which lasts for 1 year. You’ll also have access to trans-specific health care, HIV & STD testing, and PrEP adherence support.

Trans people are not at risk for HIV because of individual behaviors alone. Factors like discrimination, racism, poverty, and homelessness all have a big impact on HIV risk among people in the trans community. These same factors contribute to HIV risk resulting in high rates of HIV among trans people, especially trans women. PrEP is one tool people in the trans community can use to reduce worries about HIV.

Yes! This project will provide additional tools to help trans people adhere to a daily PrEP regimen and upon completion will provide important information on the use of PrEP in the trans community.